Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 versus placebo in uncontrolled allergic asthma (Japan, 52-week SC)
jRCT2080223065Phase 2
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma and asthma comparing QGE031 arm with Placebo arm (2 arms).
02
Drugs
ligelizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on jRCT2080223065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223065.